~ Industry veteran strengthens Tallac team with expertise in oncology clinical research and development ~...
Harnessing the power of innate and adaptive immunity to fight cancer
Tallac Therapeutics™, founded in 2018 is a privately held biopharmaceutical company based in the San Francisco Bay Area. Our multi-disciplinary team is rapidly advancing the company’s lead programs in cancer toward clinical trials in multiple indications.
Despite the success of checkpoint inhibitors and adoptive CAR-T therapies, only a fraction of cancer patients benefit. Novel therapies engaging both innate and adaptive immune response may produce more robust and durable anti-cancer immunity. We developed a novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent TLR9 agonist (T-CpG) for targeted immune activation via systemic administration. We are advancing a pipeline of therapies that enable innovative therapeutic approaches for multiple solid tumor malignancies.
We are excited to share our latest news and scientific publications.
Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting
~ Trial in Progress Poster Highlights Study Design, Dosing Regimen, and Protocol for the Ongoing...
Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
-- TAC-001 is the First Candidate from Tallac’s Novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC)...